Ustekinumab in Crohn's disease: Effectiveness and safety in clinical practice

Abstract

Abstract Introduction Ustekinumab (UST) is a monoclonal antibody against IL-12/23 approved in Spain (2017) to treat moderate/severe Crohn's disease. Objective To evaluate the effectiveness and safety in real clinical practice in patients treated with UST in our centre. Methods This is a prospective observational study including patients who started UST from 08/01/2017 to 02/28/2019 with follow-up up to that date. We analyse response and remission in weeks 16, 24 and 52, using “Crohn's Disease Activity Index” (response if 100 point decrease and remission if Results We included 61 patients with a median duration of Crohn's disease of 14.6 years (0–36). The 83.6% of patients without steroids and 73.8% without associated immunosuppressors. Previously all patients had received anti-TNF and 14.8%, in addition, vedolizumab. We observed a good correlation between Crohn's Disease Activity Index and Physician's Global Assessment (r = 0.89, p Conclusion UST is an effective and safe treatment in real clinical practice with high rates of clinical remission at week 16, 24 and 52 regardless of the order of biological used and the reason for starting UST.